Introduction
Gastrointestinal side-effects are a common accompaniment of many non-steroidal antiinflammatory drugs used for treatment of rheumatic disease. Preliminary studies with fenclofenac suggest that this drug has fewer gastrointestinal side-effects. We report here a preliminary study aimed at analysing the possible value of fenclofenac in substitution for other non-steroidal antiinflammatory drugs in patients who develop such side-effects.
Methods
Patients with chronic rheumatic disease who developed upper gastrointestinal intolerance whilst receiving non-steroidal anti-inflammatory drugs were studied. Fore-gut endoscopy was performed. The lesions assessed were cesophagitis, including minimal change lesions; erosive gastritis; peptic ulceration and duodenitis; and, when present, these were confirmed by biopsy. Following assessment, the non-steroidal anti-inflammatory drugs were withdrawn and the patients received fenclofenac instead for six weeks. The initial dose was 600 mg per day, increasing to 1200 mg per day over three weeks. The patients were assessed weekly by the gastroenterologist and by repeat endoscopy at the end of the study period. The clinical assessments included the degree of dyspepsia and the numbers of antacid tablets consumed, as well as the progress of the arthritis.
This study was performed with the patients' informed consent.
Results
So far only preliminary data on the progress of this study are available as the number of patients suitable and who will agree to the study after adequate explanation is limited. Five patients have been entered so far.
Case 1 A 58-year-old female with a one-year history of rheumatoid arthritis developed severe dyspepsia on aspirin, indomethacin and ibuprofen despite regular antacids. Endoscopy revealed chronic superficial gastritis and mild cesophagitis, confirmed by biopsy. On fenclofenac -600 mg per day, increasing to 1200 mg per dayher dyspepsia virtually disappeared, with a marked fall in antacid ingestion. However, repeat endoscopy showed no change from the previous findings. Her rheumatological status remained unaltered.
Case 2 A 36-year-old patient with rheumatoid arthritis for seven years. She was intolerant to most non-steroidal anti-inflammatory drugs, but was receiving Synacthen Depot 0.5 mg twice a week. Preliminary endoscopy showed antral gastritis confirmed by biopsy. She could not tolerate 1200 mg of fenclofenac per day because of gastrointestinal side-effects but was able to tolerate 900 mg per day without dyspepsia. Repeat endoscopy showed no evidence of gastritis. The arthritis remained under reasonable control.
Case 3
A 65-year-old female with a sixteen-year history of rheumatoid arthritis. She had severe gastrointestinal side-effects to most anti-rheumatic preparations, including D-penicillamine and steroids and was maintained on parenteral steroids. Although previous endoscopies showed gastric ulceration, the preliminary study was normal. She was able to tolerate fenclofenac without dyspepsia and with reasonable control of the arthritis. Unfortunately she developed a septicemia in the fourth week of the study and was not well enough to complete it.
Case 4
The fourth patient had osteoarthrosis of the right hip for three years. One year previously she had received phenylbutazone but a week later she was admitted to hospital with hxmatemesis and melxna. Endoscopy at ihe time showed a pre-pyloric lesser curve gastric ulcer. She was treated conservatively and discharged home. Subsequently she has continued to have dyspepsia. She took paracetamol, four to six tablets a day. She again developed further dyspeptic symptoms. At preliminary endoscopy the cesophagus, stomach and duodenum were normal. She was able to tolerate fenclofenac 1200 mg per day with only minor gastrointestinal symptoms, which did not interfere with treatment.
Case 5
A 72-year-old female with a four-year history of rheumatoid arthritis. She was initially treated with indomethacin but subsequently developed severe epigastric pain and vomiting. Barium meal and endoscopy revealed both gastric and duodenal ulcers, confirmed by biopsy (Fig 1) . Substitution with fenclofenac was satisfactory without dyspepsia and repeat endoscopy showed no abnormality (Fig 2) .
Discussion and Conclusions
This is a preliminary study with anecdotal case reports of dyspeptic arthritic patients who are able to tolerate fenclofenac in substitution for other non-steroidal anti-inflammatory drugs. The study suggests that this agent may be of value for patients with such symptoms, but many more cases will be needed before one can draw meaningful conclusions. 
